The Lancet· Mutsa Bwakura-Dangarembizi, Elizabeth Chappell, Cissy Kityo, Diana Louis Anena, Cecilia Kiilu, Moherndran Archary, Lungile Jafta, Hilda A Mujuru, Shamim Nakabuye, George P Akabwai, Abraham Siika, Rosie Mngqibisa, Henry Mugerwa, Simon Walker, Janet Seeley, David Burger, Anas Omar, Annabelle South, Hanh Nguyen, Carlo Giaquinto, Ben Spittle, Alasdair Bamford, Adeodata R Kekitiinwa, Deborah Ford, Sarah Pett, LATA trial team·· 21 天前精选AI 评分60
LATA试验：每8周注射卡博特韦-利匹韦林在非洲青少年HIV抑制维持中优于TLD
[Articles] Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial
AI 导读
LATA随机、开放标签、多中心96周非劣效性试验显示，在撒哈拉以南非洲病毒学抑制的HIV青少年中，每8周一次的长效注射卡博特韦-利匹韦林在维持病毒学抑制方面优于TLD方案，且未观察到新的安全性问题。研究结果支持长效注射卡博特韦-利匹韦林作为该人群的维持治疗选择。
推荐理由
撒哈拉以南非洲青少年HIV维持治疗的头对头96周数据，为长效注射方案在该人群的应用提供了随机对照证据。
来源：The Lancet · thelancet.com